St. Louis, MO – According to filings with the U.S. Securities and Exchange Commission, Wugen is raising $37,233,405.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dan Kemp played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Wugen
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.

To learn more about Wugen, visit http://www.wugen.com/

Contact:
Dan Kemp, President and Chief Executive Officer
314-501-1968
https://www.linkedin.com/in/kempdaniel/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved